The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic evolution from hormonal therapies and suitability of prostate cancer diagnostic specimens for metastatic prostate cancer (mPC) genomic stratification.
 
Amado J. Zurita
Honoraria - Janssen; Pfizer
Consulting or Advisory Role - AstraZeneca; Bayer
Research Funding - Infinity Pharmaceuticals
 
Ryon Graf
Employment - Epic Sciences; Foundation Medicine
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Epic Sciences; Foundation Medicine
 
Guillermo Villacampa
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - MSD; Pierre Fabre
 
Kira Raskina
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Research Funding - Foundation Medicine
 
Ethan Sokol
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Dexter X. Jin
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Richard S.P. Huang
Employment - Roche/Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Patent on IHC
 
Irene Casanova Salas
No Relationships to Disclose
 
Joan Carles
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZéneca; Bayer; Bristol-Myers Squibb; Johnson & Johnson/Janssen; MSD Oncology; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Johnson & Johnson
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera; Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag International NV (Inst); Karyopharm Therapeutics (Inst); Laboratories Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millenium Pharamceuticals (Inst); Nanobiotix (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi Aventis GmbH (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; Ipsen; Roche
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Celsius Therapeutics; Tango Therapeutics
Research Funding - Foundation Medicine
 
Alexa Betzig Schrock
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine; Roche
 
Geoffrey R. Oxnard
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Joaquin Mateo
Consulting or Advisory Role - Amgen; AstraZeneca; MSD; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Guardant Health; Janssen; Pfizer
Research Funding - AstraZeneca (Inst); Pfizer
Travel, Accommodations, Expenses - AstraZeneca